Anagliptin
Sponsors
Arima Hiroshi, Kyoto University Graduate School of Medicine, Kanazawa Medical University Diabetology and Endocrinology, JW Pharmaceutical, Institute for Clinical Effectiveness, Japan
Conditions
Coronary DiseaseDiabetes MellitusDipeptidyl-Peptidase 4 InhibitorsGlycosylated HemoglobinLDL CholesterolType 2 Diabetes MellitusType 2 Diabetes Mellitus
Type 2 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)
Phase 3
A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients
CompletedNCT01529528
Start: 2011-05-31End: 2012-11-30Updated: 2013-01-04
Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone
CompletedNCT01529541
Start: 2011-05-31End: 2013-10-31Target: 200Updated: 2014-05-14
Phase 4
Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial
CompletedNCT02330406
Start: 2015-04-30End: 2019-03-31Updated: 2019-08-28
Glycemic Variability of Combination Therapies in T2DM
RecruitingNCT07442006
Start: 2025-10-29End: 2027-03-31Target: 178Updated: 2026-03-02
Unknown Phase
Usefulness of change to anagliptin from other DPP-4 inhibitors in patients with uncontroled LDL-cholesterol
Active, not recruitingJPRN-UMIN000012329
Start: 2013-12-13Target: 20Updated: 2026-06-29
Evaluation of the clinical efficacy of anagliptin in type 2 diabetic patients with diabetic nephropathy.
Active, not recruitingJPRN-UMIN000012802
Start: 2013-10-17Target: 50Updated: 2026-06-29
ANGELS
Active, not recruitingJPRN-jRCTs041180085
Start: 2014-07-11Target: 60Updated: 2026-06-29
Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM
NCT04267601
Start: 2017-07-06End: 2021-09-30Updated: 2021-04-29